This may suggest that a previously treated population may not be suitable for the evaluation of anti-PD-L1 therapy in HER2+ BC, although the relatively restricted number of patients and limited statistical power should be considered in results’ interpretation [70]. This evidence concerns the gene ERBB2 and breast cancer.